TrialBlood2014

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.